We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

131 hedge funds and large institutions have $84.1M invested in ImmunityBio in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 11

12% more funds holding

Funds holding: 117 → 131 (+14)

10% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 30

4% less call options, than puts

Call options by funds: $4.51M | Put options by funds: $4.7M

1.5% less ownership

Funds ownership: 8.97% → 7.47% (-1.5%)

23% less capital invested

Capital invested by funds: $109M → $84.1M (-$24.6M)

Holders
131
Holders Change
+14
Holders Change %
+11.97%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
33
Reduced
30
Closed
11
Calls
$4.51M
Puts
$4.7M
Net Calls
-$190K
Net Calls Change
-$2.05M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$8.72M
2
AC
Armistice Capital
New York
+$6.98M
3
BlackRock
BlackRock
New York
+$2.64M
4
CS
Credit Suisse
Switzerland
+$1.04M
5
Group One Trading
Group One Trading
Illinois
+$897K

Top Sellers

1
DFCM
Dark Forest Capital Management
Puerto Rico
-$566K
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$537K
3
Jane Street
Jane Street
New York
-$295K
4
National Bank of Canada
National Bank of Canada
Quebec, Canada
-$193K
5
State Street
State Street
Massachusetts
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
76
Zurich Cantonal Bank
Switzerland
$32.4K – – –
Point72 Asset Management
77
Point72 Asset Management
Connecticut
$26.2K +$31.1K +15,500 New
WG
78
Winton Group
United Kingdom
$26.1K +$31K +15,438 New
TCM
79
Traynor Capital Management
Pennsylvania
$25.3K +$30K +14,950 New
WIP
80
WealthCare Investment Partners
Rhode Island
$25.3K – – –
Fidelity Investments
81
Fidelity Investments
Massachusetts
$25.1K +$19.6K +9,749 +190%
AB
82
Amalgamated Bank
New York
$25K – – –
Cambridge Investment Research Advisors
83
Cambridge Investment Research Advisors
Iowa
$25K – – –
AA
84
Aire Advisors
California
$25K +$29.7K +14,768 New
Victory Capital Management
85
Victory Capital Management
Texas
$23.7K +$28.2K +14,029 New
CLOS
86
Compagnie Lombard Odier SCmA
Switzerland
$23.7K – – –
EGM
87
Engineers Gate Manager
New York
$23K +$27.4K +13,632 New
IWC
88
Integrated Wealth Concepts
Massachusetts
$22.8K -$9.94K -4,950 -27%
LPL Financial
89
LPL Financial
California
$21.8K +$25.9K +12,917 New
LA
90
Legacy Advisors
Pennsylvania
$21.1K +$25.1K +12,500 New
MAWA
91
Moss Adams Wealth Advisors
Washington
$20.9K +$24.8K +12,341 New
RJFSA
92
Raymond James Financial Services Advisors
Florida
$20.2K -$1.71K -850 -7%
CUAMC
93
China Universal Asset Management Company
China
$19.8K +$12K +5,987 +105%
FIM
94
Freedom Investment Management
Connecticut
$19.3K +$22.9K +11,409 New
SPC
95
Sigma Planning Corp
Michigan
$18.7K – – –
NFG
96
Norris Financial Group
South Carolina
$18.6K – – –
AIP
97
Ameritas Investment Partners
Nebraska
$18.4K +$8.68K +4,322 +66%
Mirae Asset Global Investments
98
Mirae Asset Global Investments
South Korea
$18.1K -$43.9K -21,870 -67%
CC
99
Callan Capital
California
$17.8K +$21.2K +10,555 New
QT
100
Quantamental Technologies
New York
$17.2K -$602 -300 -3%
2 3
4
5 6

IBRX Hedge Fund Activity: Q3 2023 in Review

131 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2023, worth a combined $84.1M — down 23% from $109M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IBRX positions and 11 closed out — a net gain of 18 holders — while 33 added to existing stakes and 30 trimmed.

The largest buyer was Vanguard Group, adding an estimated $8.72M. The largest seller was Dark Forest Capital Management, exiting entirely with an estimated $566K sold.

  • 131 institutional investors held ImmunityBio (IBRX) as of Q3 2023, up from 117 in Q2 2023.
  • Funds reported $84.1M of ImmunityBio stock for Q3 2023, down 23% quarter-over-quarter.
  • 29 funds opened new ImmunityBio positions in Q3 2023 and 11 closed out, a net change of +18 holders.
  • The largest ImmunityBio buyer in Q3 2023 was Vanguard Group, an estimated $8.72M added.
  • The largest ImmunityBio seller in Q3 2023 was Dark Forest Capital Management, an estimated $566K sold.

Based on aggregated 13F filings for Q3 2023.